Solitary fibrous tumor of the liver with CD 34 positivity and hypoglycemia

Guglielmi, Alfredo; Frameglia, M.; Iuzzolino, P.; Martignoni, Guido; Manzoni, Giovanni De; Laterza, E; Veraldi, Gian Franco; Girlanda, R.

doi:10.1007/s005340050036

Cited by 46 publications

(49 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only 42 cases of primitive liver SFT have been described, and only 4 of those were classified as malignant [1]. Although there are no close correlations between morphology and malignant behavior, large size (more than 5 or 10 cm), sessile lesions, infiltrative margins, hypercellularity, nuclear pleomorphism, cytologic atypia, necrosis or hemorrhage and an increased mitotic index (more than 4 mitoses in 10 HPFs) have been described in malignant SFTs [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17].…”

Section: Discussionmentioning

confidence: 99%

Malignant metastasizing solitary fibrous tumors of the liver: a report of three cases

Macciò¹,

Bonetti²,

Siopis³

et al. 2015

pjp

View full text Add to dashboard Cite

Solitary fibrous tumors are rare neoplasms of mesenchymal origin that have been reported in various other extrathoracic sites, including the liver. We present a case series of three malignant solitary fibrous tumors of the liver, occurring in two women 74 and 80 years old and one 65-year-old man. No clinical features were predictive of malignancy except the large sizes and synchronous presence of lung metastases in two of the three cases. Histological examinations revealed the presence of high pleomorphic cellularity with nuclear atypia, necrosis and high mitotic ratios. All patients died of disease progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Malignant metastasizing solitary fibrous tumors of the liver: a report of three cases

Macciò¹,

Bonetti²,

Siopis³

et al. 2015

pjp

View full text Add to dashboard Cite

show abstract

“…Interestingly, association to hypoglycemia, possibly mediated by insulin growth factors, has been described in 4% to 10% of cases (7)(8)(9)(10), more often in SFT arising from peritoneum.…”

Section: Introductionmentioning

confidence: 99%

Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor Response

Stacchiotti

Negri

Palassini

et al. 2010

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Antiangiogenic treatment activity has been reported in solitary fibrous tumor (SFT), a rare and little chemosensitive sarcoma. We explored the activity of sunitinib malate (SM) in SFT and studied receptor tyrosine kinase (RTK) activation profile. Eleven patients with progressive metastatic SFT resistant to chemotherapy were treated with continuous-dosing 37.5 mg/d SM on a named-use basis. One of them also received the insulin-like growth factor I receptor (IGFIR) inhibitor figitumumab after developing secondary resistance to SM. Besides, biochemical, molecular, and fluorescence in situ hybridization analyses were done in eight naïve SFTs whose cryopreserved material was available to clarify RTK upstream and downstream signaling. In two cases treated with SM and belonging to the naïve series, both pretreatment and posttreatment samples were available. Ten patients were evaluable for response to SM. The best response according to the Choi criteria was six partial response (all with Response Evaluation Criteria in Solid Tumors stable disease), one stable disease, and three progressive disease. Responses lasted >6 months in five patients. The eight naïve samples showed high expression/phosphorylation of PDGFRB, epidermal growth factor receptor, and IGFIR/IR, in the presence of their cognate ligands. Downstream pathways revealed expression/activation of Akt, extracellular signal-regulated kinase 1-2 and, closely related to SFT subtypes, of S6 and 4E-BP1. In two patients, whose pretreatment and posttreatment clinical and molecular status were available, biochemical data confirmed the activity of SM, although they also suggested a possible time-dependent shift of dominant RTK from PDGFRB to IGFIR/insulin receptor. A Response Evaluation Criteria in Solid Tumors partial response to figitumumab corroborated these findings. SM has antitumor activity in SFT, possibly through a PDGFRB-mediated mechanism, but treatments with IGFIR/ insulin receptor and possibly epidermal growth factor receptor inhibitors are worth testing. Mol Cancer Ther; 9(5); 1286-97. ©2010 AACR.

show abstract

“…M21(i(14q)) i(14)(q10) M22(der(15)) add(15)(?::pter-q24::?) M23 (der(15;22)) der (15) Characterisation of a novel cell line (CSQT-2) T Wang et al Moreover, as is well-known, the theory of cancer stem cells argues that a cancer mass is built up by a relatively tiny portion of the total tumour, called cancer stem cells or TIC (Guglielmi et al, 1998;Bansal and Banerjee, 2009;Kawasaki et al, 2009;Tu et al, 2009). The previous research on HCC TICs found that we could separate or enrich HCC TICs through specific staining for cell surface markers, such as CD133, CD90 and EpCAM (Yang et al, 2008a, b;Yamashita et al, 2009;Yeh et al, 2009;Yoshikawa et al, 2009;Zhu et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma

Wang

Feng

et al. 2010

Br J Cancer

View full text Add to dashboard Cite

BACKGROUND: Portal vein tumour thrombus (PVTT) is highly associated with the progression and metastasis of hepatocellular carcinoma (HCC). However, there are no appropriate cell models of PVTT with which to study the biological and physiological characteristics of PVTT. METHODS: Primary cell culture was performed by the use of a successive xenograft line called PVTT-#1, which was obtained from a 60-year-old male HCC patient accompanied by PVTT. RESULTS: A successive cell line named CSQT-2 was established. The cell line showed aggressive phenotypes in terms of cell growth, survival, migration, xenograft and metastasis. Moreover, an orthotopic transplantation assay showed that PVTT can be generated in nude mice when CSQT-2 cells were inoculated in the liver and that it shows a typical migratory tendency in the vascular branches of portal vein. Moreover, the established CSQT-2 cells also showed varied expression of tumour-initiating cell (TIC) markers such as CD133, CD90 and EpCAM. CONCLUSION: Establishment of CSQT-2 may provide a suitable model with which to investigate the molecular mechanisms of PVTT-related HCC.

show abstract

Solitary fibrous tumor of the liver with CD 34 positivity and hypoglycemia

Cited by 46 publications

References 14 publications

Malignant metastasizing solitary fibrous tumors of the liver: a report of three cases

Malignant metastasizing solitary fibrous tumors of the liver: a report of three cases

Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor Response

Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma

Contact Info

Product

Resources

About